Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 7 | 332,500 | $2.88M |
| Open-market sale | 2 | 16,048 | $136K |
| Option exercise | 12 | 672,000 | |
| Tax withholding / forfeiture | 3 | 11,659 | |
| Bona-fide gift | 4 | 1,540,106 | |
| Derivative transaction | 6 | 325,800 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
43 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 50,000 | $8.79 | $439K | |
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 336,000 | $0.00 | - | |
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 627,553 | $0.00 | - | |
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 251,553 | $0.00 | - | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 34,000 | $8.62 | $293K | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 3,500 | $8.62 | $30K | |
| Wagner M. Zago - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 51,000 | $8.56 | $437K | |
| Wagner M. Zago - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 51,000 | - | - | |
| Wagner M. Zago - Officer | Option exercise | Restricted Stock Units | 51,000 | $0.00 | - | |
| Derivative | Ordinary Shares, par value $0.01 per share | 15,000 | $8.56 | $128K | ||
| Option exercise | Ordinary Shares, par value $0.01 per share | 15,000 | - | - | ||
| Option exercise | Restricted Stock Units | 15,000 | $0.00 | - | ||
| Chad J. Swanson - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 40,800 | $8.56 | $349K | |
| Chad J. Swanson - Officer | Tax withholding / forfeiture | Ordinary Shares, par value $0.01 per share | 3,467 | $8.56 | $30K | |
| Chad J. Swanson - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 51,000 | - | - | |
| Chad J. Swanson - Officer | Option exercise | Restricted Stock Units | 51,000 | $0.00 | - | |
| Brandon S. Smith - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 78,000 | $8.56 | $668K | |
| Brandon S. Smith - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 78,000 | - | - | |
| Brandon S. Smith - Officer | Option exercise | Restricted Stock Units | 78,000 | $0.00 | - | |
| Derivative | Ordinary Shares, par value $0.01 per share | 57,000 | $8.56 | $488K | ||
| Option exercise | Ordinary Shares, par value $0.01 per share | 57,000 | - | - | ||
| Option exercise | Restricted Stock Units | 57,000 | $0.00 | - | ||
| Gene G. Kinney - Officer | Derivative | Ordinary Shares, par value $0.01 per share | 84,000 | $8.56 | $719K | |
| Gene G. Kinney - Officer | Option exercise | Ordinary Shares, par value $0.01 per share | 84,000 | - | - | |
| Gene G. Kinney - Officer | Option exercise | Restricted Stock Units | 84,000 | $0.00 | - | |
| Tax withholding / forfeiture | Ordinary Shares, par value $0.01 per share | 3,498 | $8.56 | $30K | ||
| Open-market sale | Ordinary Shares, par value $0.01 per share | 7,662 | $8.47 | $65K | ||
| Michael John Isaacs - Officer | Tax withholding / forfeiture | Ordinary Shares, par value $0.01 per share | 4,694 | $8.56 | $40K | |
| Michael John Isaacs - Officer | Open-market sale | Ordinary Shares, par value $0.01 per share | 8,386 | $8.47 | $71K | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 20,000 | $7.90 | $158K | |
| William P. Scully - 10% Owner | Gift | Ordinary Shares, par value $0.01 per share | 325,000 | $0.00 | - | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 125,000 | $8.17 | $1.02M | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 50,000 | $9.31 | $465K | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 50,000 | $9.43 | $471K | |
| William P. Scully - 10% Owner | Open-market purchase | Ordinary Shares, par value $0.01 per share | 100,000 | $9.81 | $981K | |
| Daniel G. Welch | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | ||
| Lars Ekman | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | ||
| Shane Cooke | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Richard T. Collier | Grant or award | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | ||
| Wagner M. Zago - Officer | Grant or award | Stock Option (Right to Buy) | 190,000 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | ||
| Chad J. Swanson - Officer | Grant or award | Stock Option (Right to Buy) | 190,000 | $0.00 | - | |
| Brandon S. Smith - Officer | Grant or award | Stock Option (Right to Buy) | 190,000 | $0.00 | - | |
| Grant or award | Stock Option (Right to Buy) | 230,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
PROTHENA CORP PUBLIC LTD CO (PRTA) had 17 insider filings in the last 90 days, with the most recent on 2026-08-21. The full record for PRTA runs to 43 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
7 insider purchases of PRTA were filed in the last 90 days, totaling $2.88M.
2 insider sales of PRTA were filed in the last 90 days, totaling $136K.
This page tracks PRTA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PRTA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.